Skip to content
value.today
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc.

🇺🇸 Cambridge, Massachusetts, USAPharmaceuticalsFounded 2014
Total raised
$36 M
3 rounds on record
Latest round
$30 M
Jun 2020
First round on record
Mar 2014
Today
Went public
See the company page

Amylyx Pharmaceuticals, Inc. is listed today as Amylyx Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Amylyx Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$30 MNo. 3$10 to $50 million

Amylyx Pharmaceuticals, Inc.: Raise no. 3, Jun 2020

Investors in this round

17 investors had bought by the notice of Jul 1, 2020: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amylyx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joshua Cohen · Executive Officer, Director
  • Justin Klee · Executive Officer, Director
  • Peter Finn · Executive Officer
  • Felix Von Coerper · Director
  • George Milne · Director
  • Isaac Cheng · Director
  • Stephen Chubb · Director
  • Walter Gilbert · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executive Compensation”

Signed by Peter B. Finn, Secretary. Source: SEC Form D, newest notice filed Jul 1, 2020. Read the notice at the SEC.

equitySEC
Aug 2016$4 MNo. 2$2 to $10 million

Amylyx Pharmaceuticals, Inc.: Raise no. 2, Aug 2016

Investors in this round

19 investors had bought by the notice of Aug 22, 2016: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amylyx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
$15,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$620,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joshua Cohen · Executive Officer, Director
  • Peter Finn · Executive Officer
  • George Milne · Director
  • Justin Klee · Director
  • Stephen Chubb · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Peter Finn, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Aug 22, 2016. Read the notice at the SEC.

equitySEC
Mar 2014$1 MNo. 1Under $2 million

Amylyx Pharmaceuticals, Inc.: Raise no. 1, Mar 2014

Investors in this round

28 investors had bought by the notice of Nov 17, 2015: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for Amylyx Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $2 M offered; $0 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$75,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joshua Cohen · Executive Officer, Director
  • Peter B. Finn · Executive Officer · Secretary
  • George M. Milne, PH.D. · Director
  • Justin Klee · Director
  • Stephen D. Chubb · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executive Salaries”

Signed by Peter B. Finn, Secretary. Source: SEC Form D, newest notice filed Nov 17, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Amylyx Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).

    SEC Form D · Jul 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2020

That is all the official record says: Amylyx Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Amylyx Pharmaceuticals, Inc. are on record.

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in Amylyx Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
ALS Invest 1 B.V.Othernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2022)SEC Form 3
George M. Milne Jr.Personnot statednot statedHeld Series A, B, C-1 and C-2 preferred stock, director (Form 3, 2022)SEC Form 3
Joshua B. CohenPersonnot statednot statedHeld Series C-1 preferred stock, director (Form 3, 2022)SEC Form 3
Justin B. KleePersonnot statednot statedHeld Series C-1 preferred stock, director (Form 3, 2022)SEC Form 3
Morningside Venture Investments LtdVenture capitalnot statednot statedHeld Series A, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Mvil, LLCOthernot statednot statedHeld Series A, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Viking Global Investors LPFund or asset managernot statednot statedHeld Series C-1 preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Viking Global Opportunities GP LLCOthernot statednot statedHeld Series C-1 preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Viking Global Opportunities Illiquid Investments Sub-Master LPFund or asset managernot statednot statedHeld Series C-1 preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Viking Global Opportunities Parent GP LLCOthernot statednot statedHeld Series C-1 preferred stock, 10% owner (Form 3, 2022)SEC Form 3
Viking Global Opportunities Portfolio GP LLCOthernot statednot statedHeld Series C-1 preferred stock, 10% owner (Form 3, 2022)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 28 investors.

Largest shareholders today

Institutions holding Amylyx Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Amylyx Pharmaceuticals, Inc.
NameRoleNamed in
Joshua CohenExecutive officerJul 2020
Justin KleeExecutive officerJul 2020
Peter FinnExecutive officerJul 2020
Peter B. FinnSecretaryNov 2015
Felix Von CoerperDirectorJul 2020
George MilneDirectorJul 2020
Isaac ChengDirectorJul 2020
Joshua CohenDirectorJul 2020
Justin KleeDirectorJul 2020
Stephen ChubbDirectorJul 2020
Walter GilbertDirectorJul 2020
George M. Milne, PH.D.DirectorNov 2015
Stephen D. ChubbDirectorNov 2015

Went public since 2022. Its SEC number is that of a company listed on a stock exchange.